Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Increases By 35.5%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 762,600 shares, an increase of 35.5% from the January 31st total of 563,000 shares. Based on an average daily trading volume, of 642,400 shares, the days-to-cover ratio is currently 1.2 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Friday, November 15th. D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Thursday, February 27th. Finally, Alliance Global Partners initiated coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Stock Up 4.9 %

Shares of GOVX stock opened at $1.51 on Tuesday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18. The stock’s 50-day moving average is $1.98 and its two-hundred day moving average is $2.63.

Institutional Trading of GeoVax Labs

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after acquiring an additional 33,440 shares during the last quarter. Citadel Advisors LLC bought a new stake in GeoVax Labs during the 4th quarter worth about $104,000. Virtu Financial LLC acquired a new position in GeoVax Labs in the third quarter valued at approximately $97,000. Finally, Northern Trust Corp acquired a new position in shares of GeoVax Labs in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.